M pneumoniae infection is not a reportable disease, and testing is often not performed in the outpatient setting, limiting estimates of clinical prevalence and delaying recognition of community ...

"Less pain and no need for sedation are major benefits," said Jon Matthew Farber, MD, in this edition of Journal Club. A case report describes how physicians in the emergency department of a Korean ...

Efficacy for the kinase inhibitor was based on the ReNue (NCT03962543 ) trial that featured 58 adults and 56 pediatric patients. The FDA has approved mirdametinib (Gomekli; SpringWorks Therapeutics, ...

Venous thromboembolism (VTE) is a rare but life-threatening condition in pediatrics, posing unique challenges in treatment and prevention within this age group. VTE incidence in pediatric patients has ...

LIB Therapeutics has announced that the FDA has accepted its biologics license application (BLA) for lerodalcibep, a treatment designed to lower low-density lipoprotein cholesterol (LDL-C) in patients ...

Video content above is prompted by the following: 4. How do the treatment options evolve as a child ages? a. FDA labeling (dupilumab ≥ 6 months, lebrikizumab ≥ 12 years, tralokinumab ≥ 12 years, ...

Panelists discuss the role of newer agents, including biologics/monoclonal antibodies (dupilumab, tralokinumab, lebrikizumab) and Janus kinase (JAK) inhibitors (abrocitinib, baricitinib, upadacitinib) ...

Colleen Sloan, PA-C, RDN, discussed how the 5 senses can affect a child's appetite, as well as how to use food play to get children to try new foods. Imagine biting into a crisp apple, only to find it ...

The investigational biologic targets the interleukin-2 receptor complex in the body in order to stimulate proliferation of inhibitory immune cells. Rezpegaldesleukin (Rezpeg; Nektar Therapeutics) has ...

Tina Tan, MD, comments on a severe respiratory season, stresses timely vaccination ...